Osteoporose in der gynäkologischen Sprechstunde

Literatur

• 1 Felsenberg D et al. Prevalence of vertebral spinal deformities in women and men in Germany. EVOS group in Germany.  Med Klin. 1998;  93 31-34
• 2 WHO . Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group.  World Health Organ Tech Rep Ser. 1994;  843
• 3 Cooper C et al. Population-based study of survival after osteoporotic fractures.  Am J Epidemiol. 1993;  137 1001-1005
• 4 Pfeilschifter J. 2006 DVO-guideline for prevention, diagnosis, and therapy of osteoporosis for women after menopause, for men after age 60 executive summary guidelines.  Exp Clin Endocrinol Diabetes. 2006;  114 611-622
• 5 Podsiadlo D, Richardson S. The timed “Up & Go”: a test of basic functional mobility for frail elderly persons.  J Am Geriatr Soc. 1991;  39 142-148
• 6 Guralnik J M et al. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability.  N Engl J Med. 1995;  332 556-561
• 7 Gluer C C et al. Association of five quantitative ultrasound devices and bone densitometry with osteoporotic vertebral fractures in a population-based sample: the OPUS Study.  J Bone Miner Res. 2004;  19 782-793
• 8 Schott A M et al. Should age influence the choice of quantitative bone assessment technique in elderly women? The EPIDOS study.  Osteoporos Int. 2004;  15 196-203
• 9 Tsai K S et al. Impaired vitamin D metabolism with aging in women. Possible role in pathogenesis of senile osteoporosis.  J Clin Invest. 1984;  73 1668-1672
• 10 Bischoff-Ferrari H A et al. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes.  Am J Clin Nutr. 2006;  84 18-28
• 11 Siggelkow H. Vitamin D and old age.  MMW Fortschr Med. 2007;  149 36-37
• 12 Eastell R. Aromatase inhibitors and bone.  J Steroid Biochem Mol Biol. 2007;  106 157-161
• 13 Mincey B A et al. Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors.  Clin Breast Cancer. 2006;  7 127-132
• 14 Hillner B E et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer.  J Clin Oncol. 2003;  21 4042-4057
• 15 Aapro M et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel.  Ann Oncol. 2007; 
• 16 Winer E P et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.  J Clin Oncol. 2005;  23 619-629
• 17 Wisser J et al. Changes in bone density and metabolism in pregnancy.  Acta Obstet Gynecol Scand. 2005;  84 349-354
• 18 Lanham S A et al. Intrauterine programming of bone. Part 1: Alteration of the osteogenic environment.  Osteoporos Int. 2007; 
• 19 Lanham S A et al. Intrauterine programming of bone. Part 2: Alteration of skeletal structure.  Osteoporos Int. 2007; 
• 20 Kovacs C S. Calcium and bone metabolism during pregnancy and lactation.  J Mammary Gland Biol Neoplasia. 2005;  10 105-118
• 21 Hellmeyer L et al. The use of i. v. bisphosphonate in pregnancy-associated osteoporosis: case study.  Exp Clin Endocrinol Diabetes. 2007;  115 139-142
• 22 Steib-Furno S et al. Pregnancy-related hip diseases: incidence and diagnoses.  Joint Bone Spine. 2007;  74 373-378
• 23 O'Sullivan S M et al. Bisphosphonates in pregnancy and lactation-associated osteoporosis.  Osteoporos Int. 2006;  17 1008-1012